Amylyx Pharmaceuticals Inc (AMLX)
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing treatments for neurodegenerative diseases and endocrine disorders in the United States. Its pipeline includes avexitide, an investigational GLP-1 receptor antagonist being studied in phase 3 trials for post-bariatric hypoglycemia and congenital hyperinsulinism. The company is also advancing AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol, in phase 2 development for wolfram syndrome and in phase 2b/3 testing for progressive supranuclear palsy. Additional programs include AMX0114 for amyotrophic lateral sclerosis, along with longer-acting and other GLP-1 receptor antagonist candidates aimed at post-bariatric hypoglycemia and rare diseases. Founded in 2013, Amylyx is headquartered in Cambridge, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AMLX
|
$20.48
|
-36.8% Downside
|
Overvalued
|
$42.36
|
30.7% Upside
|
Undervalued
|
Fair
|
0.0%
|
November 5, 2026
|
17.0x
|
4.068 B
|
3.822 B
|
0.1%
|
87.3%
|
95.3
|
83.3%
|
